Lilly Covid antibodies cut hospitalizations and deaths
US pharmaceutical company Eli Lilly’s combination of two synthetic antibodies against COVID-19 reduced hospitalizations and deaths by 70 percent in high-risk patients with recent positive tests, the company said Tuesday.